Soleno Therapeutics (SLNO) Accounts Payables (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Accounts Payables data on file, last reported at $12.4 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $12.4 million, up 125.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.4 million (up 125.9% YoY), and the FY2025 annual result was $12.4 million, up 40.0% from the prior year.
• Accounts Payables held at $12.4 million in Q1 2026 per SLNO's latest filing, from $12.4 million in the prior quarter.
• Over five years, Accounts Payables peaked at $12.4 million in Q4 2025 and troughed at $1.8 million in Q4 2022.
• A 5-year average of $5.5 million and a median of $3.7 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2024: Accounts Payables plunged 48.36% in 2022, then soared 188.77% in 2024.
• A 5-year view of Accounts Payables shows it stood at $1.8 million in 2022, then soared by 77.21% to $3.1 million in 2023, then jumped by 182.06% to $8.9 million in 2024, then soared by 40.0% to $12.4 million in 2025, then slipped by 0.39% to $12.4 million in 2026.
• Business Quant data shows SLNO's Accounts Payables at $12.4 million in Q1 2026, $12.4 million in Q4 2025, and $8.1 million in Q3 2025.